NCT01389466View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Step 1

Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days

BIOLOGICAL

Step 2

Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days

Trial Locations (4)

Unknown

Korea University Ansan Hospital, Ansan

Inha University Hospital, Inchon

Korea University Guro Hospital, Seoul

Catholic University Of Korea ST. Vincent's Hospital, Suwon

Sponsors
All Listed Sponsors
collaborator

Korean Center for Disease Control and Prevention

OTHER_GOV

lead

Green Cross Corporation

INDUSTRY

NCT01389466 - Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter